Whole-body low-dose CT can be of value in prostate cancer decision-making: a retrospective study on 601 patients.

Mohammadreza ChavoshiSeyed Ali MirshahvaladSara ZamaniAmir Reza RadmardBabak FallahiSeyed Asadollah Mousavi

Published in: Insights into imaging (2023)

The whole-body low-dose CT can be considered valuable in the clinical decision-making of prostate cancer patients. This modality may obviate performing multiple imaging sessions and high-cost scans in patients diagnosed with the high-burden disease.

Keyphrases

prostate cancer
low dose
end stage renal disease
ejection fraction
newly diagnosed
decision making
prognostic factors
magnetic resonance imaging
high dose
patient reported outcomes
high resolution
magnetic resonance
risk factors
photodynamic therapy
dual energy
patient reported